The CRL comes after the FDA accepted the NDA for review in October 2025 and set a Prescription Drug User Fee Act target ...

By Siddhi Mahatole June 2 (Reuters) - Drug developer Cingulate said on Tuesday the U.S. Food and Drug Administration declined ...

The cingulate cortex occupies a medial position in the cerebral hemispheres and extends from the frontal lobe (anterior cingulate cortex, ACC) through the midcingulate region (MCC) to the ...

KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to ...

Cingulate Inc. has been granted a European patent for its ADHD treatment, CTx-1301. Following the patent news, Cingulate's stock has surged by 302.9%, reflecting strong market confidence in the ...

The FDA rejected Cingulate Inc.'s ADHD medicine application over manufacturing issues. Cingulate holds nearly $30 million in ...

Biopharma company Cingulate announced a joint commercialization agreement with Indegene this week, which pushes forward Cingulate’s lead drug candidate for attention deficit/hyperactivity disorder ...

Cingulate Inc. (NASDAQ:CING) is one of the best NASDAQ growth stocks to buy and hold forever. On March 18, Cingulate reported its financial results for Q4 and the full year 2025, highlighting the ...

A team of researchers at the Korea Advanced Institute of Science and Technology, has found a microcircuit in the mouse anterior cingulate cortex (ACC) that appears to play a role in transforming ...

Can drug delivery technology equip Cingulate to win market share from Johnson & Johnson, Novartis and Takeda? That is the question facing investors as they weigh up whether to back Cingulate’s pitch ...